Hypoxia Affects Neprilysin Expression Through Caspase Activation and an APP Intracellular Domain-dependent Mechanism by Caroline Kerridge et al.
ORIGINAL RESEARCH
published: 13 November 2015
doi: 10.3389/fnins.2015.00426
Frontiers in Neuroscience | www.frontiersin.org 1 November 2015 | Volume 9 | Article 426
Edited by:
Ritchie Williamson,
University of Bradford, UK
Reviewed by:
Bogdan A. Stoica,
University of Maryland School of
Medicine, USA
Peng Lei,
The University of Melbourne, Australia
*Correspondence:
Natalia N. Nalivaeva
n.n.nalivaeva@leeds.ac.uk;
Anthony J. Turner
a.j.turner@leeds.ac.uk
Specialty section:
This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neuroscience
Received: 30 July 2015
Accepted: 20 October 2015
Published: 13 November 2015
Citation:
Kerridge C, Kozlova DI, Nalivaeva NN
and Turner AJ (2015) Hypoxia Affects
Neprilysin Expression Through
Caspase Activation and an APP
Intracellular Domain-dependent
Mechanism. Front. Neurosci. 9:426.
doi: 10.3389/fnins.2015.00426
Hypoxia Affects Neprilysin
Expression Through Caspase
Activation and an APP Intracellular
Domain-dependent Mechanism
Caroline Kerridge 1, 2, Daria I. Kozlova 3, Natalia N. Nalivaeva 1, 3* and Anthony J. Turner 1*
1 Faculty of Biological Sciences, School of Molecular and Cellular Biology, University of Leeds, Leeds, UK, 2Neuroscience,
Eli Lilly and Company Limited, Lilly Research Centre, Surrey, UK, 3 I. M. Sechenov Institute of Evolutionary Physiology and
Biochemistry, Russian Academy of Sciences, St. Petersburg, Russia
While gene mutations in the amyloid precursor protein (APP) and the presenilins lead to
an accumulation of the amyloid β-peptide (Aβ) in the brain causing neurodegeneration
and familial Alzheimer’s disease (AD), over 95% of all AD cases are sporadic. Despite
the pathologies being indistinguishable, relatively little is known about the mechanisms
affecting generation of Aβ in the sporadic cases. Vascular disorders such as ischaemia
and stroke are well established risk factors for the development of neurodegenerative
diseases and systemic hypoxic episodes have been shown to increase Aβ production
and accumulation. We have previously shown that hypoxia causes a significant decrease
in the expression of the major Aβ-degrading enzyme neprilysin (NEP) which might
deregulate Aβ clearance. Aβ itself is derived from the transmembrane APP along with
several other biologically active metabolites including the C-terminal fragment (CTF)
termed the APP intracellular domain (AICD), which regulates the expression of NEP and
some other genes in neuronal cells. Here we show that in hypoxia there is a significantly
increased expression of caspase-3, 8, and 9 in human neuroblastoma NB7 cells, which
can degrade AICD. Using chromatin immunoprecipitation we have revealed that there
was also a reduction of AICD bound to the NEP promoter region which underlies the
decreased expression and activity of the enzyme under hypoxic conditions. Incubation
of the cells with a caspase-3 inhibitor Z-DEVD-FMK could rescue the effect of hypoxia on
NEP activity protecting the levels of AICD capable of binding the NEP promoter. These
data suggest that activation of caspases might play an important role in regulation of NEP
levels in the brain under pathological conditions such as hypoxia and ischaemia leading
to a deficit of Aβ clearance and increasing the risk of development of AD.
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INTRODUCTION
Cerebral hypoxia is a condition in which the brain is deprived of oxygen and, as a result, cells elicit
a wide range of adaptive responses and major metabolic alterations. Currently, vascular disorders
such as ischaemia and stroke are considered as established risk factors for the development of
neurodegenerative diseases, in particular of Alzheimer’s disease (AD) (O’Brien and Markus, 2014).
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The pathology in familial AD is caused by overproduction and
accumulation in the brain of abnormally high concentrations
of the amyloid-β (Aβ) peptide and its oligomers causing
synaptic loss and neuronal cell death (Hardy and Higgins,
1992; Walsh et al., 2002; Hardy, 2009). It is now becoming
evident, however, that Aβ levels in the brain represent a
dynamic equilibrium between its production from the amyloid
precursor protein (APP) and removal by a cohort of amyloid
clearance proteins which can be either enzymes (proteases) or
binding/transport proteins. The group of enzymes capable of
proteolytic degradation of Aβ currently embraces more than 20
members (for review, see Nalivaeva et al., 2012a, 2014). Several
of the main amyloid-degrading enzymes (ADEs) are members
of the neprilysin peptidase family: NEP, NEP2 and endothelin
converting enzymes (ECE-1 and ECE-2) (Turner, 2003; Marr
and Spencer, 2010; Nalivaeva et al., 2012a; Pacheco-Quinto
and Eckman, 2013). Another metallopeptidase which plays an
important role in Aβ metabolism is insulin-degrading enzyme
(IDE) (Qiu and Folstein, 2006; Leissring and Turner, 2013).
With aging and under pathological conditions expression levels
and activity of these enzymes decline (Nalivaeva et al., 2004;
Caccamo et al., 2005; Kochkina et al., 2015) leading to an amyloid
clearance deficit, which is now considered to be one of the major
factors of the sporadic form of AD (Selkoe, 2012; Pluta et al.,
2013).
As we have shown earlier, hypoxia leads to reduced NEP
levels and activity both in cellular models and in vivo (Nalivaeva
et al., 2004, 2012b; Fisk et al., 2007). A prolonged exposure
to a hypoxic environment has also been reported to increase
Aβ levels significantly accelerating the hyperphosphorylation
of tau and contributing to neuronal cell death (Jendroska
et al., 1995; Li et al., 2009; Fang et al., 2010). Regulation of
NEP expression is complex as the enzyme appears to have
a constitutive regulatory pathway (D’Adamio et al., 1989; Li
et al., 1995) as well as an epigenetically-regulated component
(Pardossi-Piquard et al., 2005; Belyaev et al., 2009). The latter
involves competitive binding of a transcription factor, namely the
APP intracellular domain (AICD) produced in the β-secretase
amyloidogenic pathway (Belyaev et al., 2010), to the NEP gene
promoter leading to activation of mRNA synthesis while histone
deacetylases inhibit this process. As the effects of hypoxia on
NEP expression may represent an important pathological trigger
in AD, the factors affecting NEP dysregulation under these
conditions need to be better understood. AICD is an extremely
labile peptide being a substrate of various intracellular peptidases
including caspases (Bertrand et al., 2001) which might result
in dysregulation of AICD-dependent NEP expression under
various pathological conditions related to caspase activation. In
particular, hypoxia was shown to be accompanied by increased
levels of caspase expression and activity in the brain (Khurana
et al., 2002). The aim of this study was to assess whether
activation of caspases might be a factor leading to dysregulation
of NEP gene expression and activity under hypoxic conditions.
For this we have employed human neuroblastoma NB7 cells
which possess high endogenous levels of NEP and, as has
been demonstrated, are responsive to hypoxia (Fisk et al., 2007;
Belyaev et al., 2009).
METHODS
Cell Culture and Hypoxia Treatment
The NB7 (SJ-N-CG) neuroblastoma cell line, which expresses
high endogenous levels of NEP, was obtained from St Jude
Children’s Research Hospital (Memphis, USA, kind gift of Dr.
Vincent J. Kidd). The NB7 cells were cultured in RPMI-1640
media supplemented with 10% (v/v) fetal bovine serum, 50
units/ml penicillin, 50µg/ml streptomycin and 2mM glutamine
(all from Cambrex Bio Science Ltd., Wokingham, Berkshire, UK)
at 37◦C in 5% (v/v) CO2 and sub-cultured every 7 days. After
reaching the confluent stage, cells were incubated in an O2/CO2
incubator (MC0-175M, Sanyo) for 24 h under 1% O2. The cells
were collected 24 (or 48 h) later, washed twice with 10ml PBS,
scraped into 10ml of PBS (pH 7.2), pelleted at 3000 g for 5min
and used for mRNA and protein content analysis as well as for
the activity assays.
Cell Viability Determination by Trypan Blue
Exclusion
Cells were washed twice in PBS, incubated in trypsin/EDTA
for 5min at 37◦C and knocked from the surface of the flask
prior to adding 5ml of media then pelleting at 400 g for 5min.
Pellets were resuspended in 1ml of media and a 1:1 dilution
of cell suspension in 4% trypan blue was prepared. Twenty
microlitres of cell suspension was loaded under a cover slip on
a haemocytometer and allowed to fill the chambers by capillary
action. The number of total and viable cells was determined by
viewing under a light microscope at 40X magnification. Non-
viable cells take up the trypan blue and appear dark (Strober,
2001).
Gene Expression Analysis
Cell RNA was prepared using the RNeasy extraction kit (Qiagen,
Crawley, UK) according to themanufacturer’s protocol. RNAwas
treated with DNase I (Invitrogen, Paisley, UK) and cDNA was
prepared using the iScript cDNA kit (BioRad, UK). cDNA was
amplified using conventional PCR or real-time PCR as in Zuccato
et al. (2007). DNA amplified by conventional PCR was analyzed
in 2% agarose gels containing ethidium bromide (1µg/ml) and
visualized on a Molecular Imager Gel Doc XR System with
Quantity One 4.6.1 programme (BioRad). Image densitometry
was performed using Aida Array Analyzer 4.15 software. Real-
time PCR was performed in an iCycler Thermal Cycler with
Multicolour PCR detection system, (Biorad, Hercules, CA) using
SYBR Green (BioRad) incorporation and expression reported
relative to actin mRNA. Primer sequences used were as follows:
NEP F- CCTGGAGATTCATAATGGATCTTGT
R- AAAGGGCCTTGCGGAAAG
Caspase-1 F- TGCTTTCTGCTCTTCAACACC
R-CACAAGACCAGGCATATTCTTTC
Caspase-3 F-GAGGCCGACTTCTTGTATGC
R-AATTCTGTTGCCACCTTTCG
Caspase-8 F-AGAGCCTGAGGGAAAGATGTC
R-TCACATCATAGTTCACGCCAGT
Caspase-9 F-CGTGGTGGTCATCCTCTCTC
R-GAGCATCCATCTGTGCCATA
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U6 F- CTCGCTTCGGCAGCACA
R- AACGCTTCACGAATTTGCGT
Actin F- CGCAGCAGTCAGGGACATTT
R- TTCACATACAGCTTGGGAAGC
Preparation of Cell Lysates
Cells were washed twice with phosphate-buffered saline (PBS:
1.5mM KH2PO4, 2.7mM Na2HPO4, 150mM NaCl, pH 7.4),
harvested and pelleted by centrifugation. For detection of
proteins from cell lysates, cells were lysed in RIPA buffer
[10mM Tris/HCl pH 8.0, 150mM NaCl, 1% (v/v) Nonidet P-
40, 0.5% (w/v) sodium deoxycholate, 5mM EDTA, 1X complete
inhibitor mix (Roche diagnostics)] on ice for 20min. Lysates
were homogenized through 22 G needles 10 times then clarified
by centrifugation at 2800 g for 10min. Protein concentration of
lysates was determined using the bicinchoninic acid (BCA) assay
(Sigma Aldrich).
Electrophoresis and Western Blotting
Samples (30µg or, for AICD detection, 50µg, protein)
were resolved on 10% polyacrylamide gels or, for AICD
detection, 10–20% tricine gels (Invitrogen, Paisley, UK), and
transferred onto Hybond-P poly(vinylidene) difluoride (PVDF)
membranes (Amersham Life Sciences, Buckinghamshire, UK).
The membranes were blocked overnight at 4◦C in Tris-buffered
saline (TBS: 50mM Tris, 150mM NaCl) containing 0.1%
(v/v) Tween-20 (TBST) and 5% (w/v) skimmed milk powder.
Membranes were incubated with the primary antibodies for
3 h. Primary antibodies used for blotting included: NEP (1:100,
mouse monoclonal, NCL-CD10-270, Novocastra, Newcastle, UK
or rabbit anti-rat polyclonal antibody, US Biological); GLUT-
1 (1:500, rabbit polyclonal, from Prof. S. Baldwin, University
of Leeds); anti- β-actin (1:500, rabbit polyclonal, Sigma-
Aldrich Co., Poole, Dorset, UK); anti-APP C-Terminal fragment
A8717 and anti-actin (both Sigma-Aldrich) used at 1:1000
and 1:10,000, respectively. Membranes were washed in TBST
for 1 h before incubation with peroxidase-conjugated rabbit
anti-mouse or donkey anti-rabbit secondary antibodies (GE
Healthcare, Bucks, UK) at a dilution of 1:4000. Membranes were
washed further before detection of proteins using the enhanced
chemiluminescencemethod.Western blots were quantified using
AIDA image analyzer v.4.22 (Straubenhardt, Germany).
Neprilysin Activity Assay
NEP activity was measured in a two-step coupled fluorescence
assay. NEP cleaves between Ala-Phe of the fluorogenic substrate
succinoyl-Ala-Ala-Phe-7-amido-4-methylcoumarin (Mumford
et al., 1980) and, in the presence of leucine aminopeptidase,
releases the fluorophore (AMC) from Phe and prevents
quenching allowing fluorescence to be detected. Protein samples
(1µg) were loaded into opaque 96-well plates in 100mM
Tris-HCl (pH 7.4) with or without 20µM of the NEP inhibitor
thiorphan and incubated at 37◦C for 20min. The substrate Suc-
AAF-AMC (50µM) and Leu-aminopeptidase (40 munits/ml)
were added to each well (100µl total volume/well) and
fluorescence was observed on a FLUOstar Omega multidetection
microplate reader (excitation = 355 nm, emission = 460 nm) at
suitably frequent time points. NEP activity was determined as the
difference between fluorescence measurements in the absence
and presence of 20µM thiorphan.
Caspase 3/7 Activity Assay
Caspase-3 and caspase-7 activities were determined using
a luminescent Caspase-Glo R© 3/7 activity assay (Promega,
Southampton, UK) as per manufacturers’ instruction. Briefly,
approximately 20,000 cells were added to each well of a 96
well, white-walled plate. At room temperature, the Caspase-
Glo reagent was made up by mixing the Caspase-Glo substrate
with the Caspase-Glo buffer and 100µl was added to each well.
Contents were mixed by shaking for 1min then incubated at
37◦C for 1 h. Luminescence was measured on aMicroLumat Plus
LB 96V (Berthold Technologies).
Chromatin Immunoprecipitation Analysis
ChIP was performed as described previously (Zuccato et al.,
2007; Belyaev et al., 2009). Cells were fixed, extracts sonicated
and, following incubation with protein-G-Sepharose, primary
antibodies were applied overnight. After de-crosslinking and
DNA extraction, analysis was performed by real time PCR. Data
are represented as the fold enrichment of DNA pulled down
with the specific antibody over that immunoprecipitated with
IgG. Antibodies used were anti-AICD (Covance, Harrogate) and
anti-IgG (mouse) (negative control) (Abcam). Promoter primer
sequences used were as follows:
NEP F- GGTGCGGGTCGGAGGGATGC
R- CTCCCAGCGCCCTGGGCGCTCG
Statistics
All results are given as mean ± SEM from at least three
experiments. Results were compared using unpaired two-tailed
Student’s t-test with a threshold of p < 0.05.
RESULTS
Cell Viability and GLUT1 Expression in NB7
Cells after Hypoxia
Hypoxia elicits a wide range of cellular adaptations and the
severity and duration of a hypoxic episode can significantly
affect hypoxia-induced apoptosis (Banasiak and Haddad, 1998).
In order to show that the NB7 cells were responding to hypoxic
conditions and were still viable, a cell viability assay was carried
out as well as a Western blot analysis of the established hypoxia
marker, GLUT1. Acting through the hypoxia- inducible factor-1,
GLUT-1 expression is enhanced in hypoxia, stimulating glucose
transport and maintaining cell homeostasis (Ouiddir et al.,
1999; Zhang et al., 1999). After incubation at 1% O2 for 24 h,
the viability of NB7 cells was not significantly different from
those incubated under normal conditions (Figure 1A). In both
conditions cell viability was above 90%. Although GLUT1 protein
content was detected at high levels in both normoxia and hypoxia
incubated cells, 24 h of hypoxia increased GLUT-1 protein levels
significantly suggesting that the cells were responding to hypoxic
insult by changing the level of expression of hypoxia-related
genes (Figure 1B).
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FIGURE 1 | The effects of hypoxia on cell viability and GLUT1 protein
levels in NB7 cells. (A) A cell viability assay carried out in NB7 cells
subjected to 24 h normoxia or hypoxia (1% O2). (B) Representative Western
blot and calculation of GLUT1 levels in whole cell lysates of NB7 cells
subjected to 24 h normoxic or hypoxic (1% O2) conditions. Bars represent
mean ± SEM, *p < 0.05 (n = 3).
The Effects of Hypoxia on NEP mRNA
Expression, Protein Level, and Activity
Assessing the effect of hypoxia on NEP expression in NB7 cells
we have confirmed that bothNEPmRNA and protein levels in the
cells subjected to hypoxia for 24 h were reduced by approximately
30% compared to the control cells (Figures 2A,B). Similarly, a
fluorogenic NEP enzyme activity assay has demonstrated that
NEP activity was reduced in hypoxia by approximately 40%
(Figure 2C).
The Effects of Hypoxia on mRNA
Expression and Activity of Members of the
Caspase Family
Caspases are a family of cysteine proteases that are crucial
mediators of apoptosis. Hypoxic conditions are known to induce
cellular apoptosis and the family of caspases are participants in
the hypoxia-induced apoptotic cascade (Khurana et al., 2002;
Li et al., 2005). In order to investigate the effect of hypoxia
on the expression of caspases in our cellular model, mRNA
levels for caspases-1, -8, and -9 were determined by real-time
PCR and a caspase-3/-7 activity assay was also carried out. A
three to five-fold increase in mRNA was detected for caspase-
1 and -9 (Figures 3A,C). In accordance with other studies
(Finlay et al., 2010), caspase-8 expression was extremely low
in the NB7 cells. However, despite endogenously low levels,
hypoxia also increased its mRNA expression (Figure 3B). Since
caspase-3 and caspase-7 exhibit similar substrate specificity, the
analysis of their activity was combined. Total caspase -3/-7
activity was increased by approximately four-fold in the NB7
cells incubated in hypoxic conditions compared with control
(Figure 3D).
The Effect of Hypoxia on AICD Enrichment
of the NEP Promoter
The APP C-terminal fragments (CTFs) have been identified as
a target for caspase cleavage due to the presence of a caspase-
specific cleavage site at aspartate residue 664 (for APP695 isoform)
in the APP molecule (Weidemann et al., 1999). As caspases
appear to be significantly elevated in hypoxia, ChIP analysis was
used to determine whether the reduction in NEP may be due
to reduced AICD binding to the NEP promoter region. After
24 h hypoxic incubation, AICD enrichment on theNEP promoter
region was found to be significantly reduced by approximately
five-fold (Figure 4B).
The Effects of Caspase Inhibition in
Hypoxia on NEP Activity and AICD
Enrichment on the NEP Promoter
Caspase-3 has been identified as the predominant caspase
involved in the cleavage of the APP-CTF, including AICD
(Gervais et al., 1999), therefore in order to investigate
whether caspase-3 is involved in the reduction of AICD-
induced NEP expression, cells were subjected to hypoxia
with or without the caspase-3 inhibitor, Z-DEVD-FMK. As
previously shown, NEP activity was significantly reduced in
hypoxia compared to control, but cell treatment with the
caspase-3 inhibitor restored NEP activity to approximately
90% of the control level (Figure 4A). Similarly, ChIP
analysis has revealed that caspase inhibitor treatment to a
significant extent protected the level of AICD binding to
the NEP gene promoter (Figure 4B). This testifies to the
role of caspases, and especially of caspase-3, in reduction
of NEP expression in neuronal cells subjected to hypoxic
conditions.
DISCUSSION
Hypoxia is an established factor for AD and brain deprivation
of oxygen has been associated with an increase in Aβ levels and
plaque deposition (Jendroska et al., 1995; Zhang and Le, 2010).
The leading factor in Aβ accumulation might be deficit of its
major degrading peptidase, NEP. Indeed, dysregulation of NEP
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FIGURE 2 | The effects of hypoxia on NEP expression and activity. (A) NEP mRNA expression levels normalized to U6; (B) NEP protein levels showing a
representative blot with CD10 antibody against human NEP and β-actin as loading control; (C) NEP enzyme activity (nmol/min/mg) in NB7 cells subjected to 24 h
normoxia or 24 h hypoxia (1% O2). Bars represent mean ± SEM, *p < 0.05 (n = 5).
after exposure to hypoxia has been reported in many areas of the
body including the lungs (Carpenter and Stenmark, 2001; Wick
et al., 2011), carotid body (Kumar et al., 1990), eye (Hara et al.,
2006), and brain (Nalivaeva et al., 2004, 2012b; Oh-hashi et al.,
2005). The data of the present study report significantly reduced
NEP expression and activity in the human neuroblastoma NB7
cell line subjected to hypoxia, which are consistent with other
reports.
Oxygen homeostasis is regulated by the hypoxia inducible
factor (HIF)-1α (for review see Semenza, 2006). HIF-1α
binds specifically to the hypoxia-responsive element (HRE)
in gene promoter regions and in hypoxic conditions which
can significantly alter cellular gene expression. The effects
of hypoxia on APP processing have been widely studied
and it is now well established that hypoxia increases the
amyloidogenic pathway by facilitating the up-regulation of
expression of β-secretase (BACE1), as well as components
of the γ-secretase complex resulting in increased production
both of Aβ40 and Aβ42 (Sun et al., 2006; Wang et al.,
2006; Zhang et al., 2007; Li et al., 2009). Sequence analysis,
mutagenesis and gel shift studies have revealed the binding
of HIF-1α to both the BACE1 and APH-1A promoter regions
and Notch processing has also been increased after hypoxic
incubation (Wang et al., 2006; Zhang et al., 2007). Hypoxia
has also been shown to decrease levels of metalloproteinases
ADAM10 and ADAM17 expression and consequently reduce
APP processing through the non-amyloidogenic, α-secretase
pathway (Webster et al., 2004; Rybnikova et al., 2012). A
reduction in mature ADAM10 and a concomitant increase in
immature ADAM10 has also been reported to alter the regulation
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FIGURE 3 | The effect of hypoxia on caspase-1,-8, and -9 mRNA expression and caspase -3/-7 activity levels. Expression levels of (A) caspase-1,
(B) caspase-8, (C) caspase-9 normalized to U6 in NB7 cells subjected to 24 h normoxia or 24 h hypoxia (1% O2). (D) Caspase-3/-7 activity levels in NB7 cells
subjected to 24 h normoxia or 24 h hypoxia (1% O2). Bars represent mean ± SEM, *p < 0.05, **p < 0.01.
of α-secretase APP processing in hypoxia (Auerbach and Vinters,
2006).
The data in this paper provide evidence for an alternative
mechanism by which hypoxia may increase Aβ levels. The
hypoxia-induced activation of caspases may cause an increased
cleavage of the APP-CTF and thus reduce AICD levels. This
then results in the down-regulation of the AICD-mediated gene
NEP and reduction of enzyme expression and activity which
inevitably will lead to increase of Aβ content. It has been proven
both in cell and animal models that NEP deficit is one of the
factors leading to increased Aβ production and load in the brain
(Iwata et al., 2000; Hanson et al., 2011) and up-regulation of
NEP, on the contrary, leads to reduction of Aβ levels (Mohajeri
et al., 2004; Kerridge et al., 2014). We have also shown that
caspase-3 inhibition using the potent DEVD caspase inhibitor
can protect NEP activity in the hypoxic conditions. Similar
findings have been reported in dying motor-neurons deprived of
trophic support. This type of cellular stress was shown to cause
an increase in the expression of APP and the cell death protease
caspase-3, as well as a concomitant increase in neurotoxic Aβ
(Barnes et al., 1998). Although AICD and NEP levels were not
investigated, treatment with a caspase-3 inhibitor significantly
reduced the Aβ peptide content in these types of cells. Apoptotic
stimuli activating the caspase-3 protease family have also been
reported to cleave both PS1 and PS2 (Kim et al., 1997). As
such, an alternative mechanism could involve an altered γ-
secretase cleavage of APP thus generating APP-CTF incapable of
translocating to the nucleus and/or regulating the transcription
of NEP.
It was demonstrated that hypoxia affects NEP gene expression
via histone modifications on its promoter region (Wang et al.,
2011) which can affect accessibility of AICD to its binding site. As
we have shown here, AICD binding to the NEP gene promoter
is indeed reduced under hypoxic conditions but this decrease
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FIGURE 4 | The effect of a caspase-3 inhibitor on NEP activity and
AICD binding to the NEP promoter in hypoxia. (A) NEP enzyme activity
(nmol/min/mg) and (B) enrichment of AICD on the NEP promoter analyzed by
ChIP in NB7 cells subjected to 24 h normoxia or 24 h hypoxia (1% O2) with or
without the caspase-3 inhibitor, Z-DEVD-FMK (100µM, 24 h). Bars represent n
of 3 ± SEM, *p < 0.05 compared to control, #p < 0.05 compared to hypoxia.
can be prevented by a caspase inhibitor. Because inhibition of
caspase activity does not restore completely the level of AICD
binding to the NEP promoter observed in the control cells, it
is reasonable to suggest that either there are other peptidases
active under hypoxic conditions that degrade AICD, or changes
in the NEP promoter structure due to histone deacetylation
are still interfering with its activation by AICD. As we have
shown previously (Belyaev et al., 2009; Nalivaeva et al., 2012b),
inhibition of histone deacetylases by valproic acid leads to
significant but not complete restoration of NEP gene expression
andNEP enzyme activity after hypoxia which confirms the role of
histone modifications in NEP regulation under reduced oxygen
supply.
AICD was also shown to regulate HIF-1α expression
(Kaufmann et al., 2013) and, therefore, decreased levels of
this transcription factor under hypoxic conditions might result
in a modified response of cells to hypoxic insults. As we
have established, the Aβ-clearing protein TTR is also AICD-
regulated (Kerridge et al., 2014) and is shown to be responsive
to hypoxia (Ahmad et al., 2014). Alterations of the levels
of this protein under hypoxic conditions may also affect
amyloid metabolism leading to dysbalance of its production and
clearance.
There is an increasing body of evidence that AICD levels can
be regulated by various pharmacological agents (Eisele et al.,
2007; Bauer et al., 2011; Kerridge et al., 2014) which opens
an avenue for designing a therapeutic strategy for regulating
important AICD-dependent genes. Because AICD-regulated
genes have different roles in amyloid metabolism and are cell-
and tissue-specific (for review see Beckett et al., 2012; Pardossi-
Piquard and Checler, 2012) understanding the effect of various
physiological conditions on its ability to regulate expression of
themajor amyloid-degrading enzyme is of great importance. This
work extends further our knowledge about the role of hypoxia in
NEP regulation via AICD and shows that caspase inhibitors can
be potentially beneficial for protecting the brain against harmful
effects of low oxygen supply.
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